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768Objective: To define subgroups at high risk of local recurrence (LR) after surgery for non–small cell lung cancer
using a recursive partitioning analysis (RPA).
Methods: This Institutional Review Board–approved study included patients who underwent upfront surgery
for I-IIIA non–small cell lung cancer at Duke Cancer Institute (primary set) or at other participating institutions
(validation set). The 2 data sets were analyzed separately and identically. Disease recurrence at the surgical
margin, ipsilateral hilum, and/or mediastinum was considered an LR. Recursive partitioning was used to build
regression trees for the prediction of local recurrence-free survival (LRFS) from standard clinical and patholog-
ical factors. LRFS distributions were estimated with the Kaplan-Meier method.
Results: The 1411 patients in the primary set had a 5-year LRFS rate of 77% (95% confidence interval [CI],
0.74-0.81), and the 889 patients in the validation set had a 5-year LRFS rate of 76% (95% CI, 0.72-0.80).
The RPA of the primary data set identified 3 terminal nodes based on stage and histology. These nodes and their
5-year LRFS rates were as follows: (1) stage I/adenocarcinoma, 87% (95%CI, 0.83-0.90); (2) stage I/squamous
or large cell, 72% (95% CI, 0.65-0.79); and (3) stage II-IIIA, 62% (95% CI, 0.55-0.69). The validation RPA
identified 3 terminal nodes based on lymphovascular invasion (LVI) and stage: (1) no LVI/stage IA, 82% (95%
CI, 0.76-0.88); (2) no LVI/stage IB-IIIA, 73% (95% CI, 0.69-0.80); and (3) LVI, 58% (95% CI, 0.47-0.69).
Conclusions: The risk of LR was similar in the primary and validation patient data sets. There was discordance
between the 2 data sets regarding the clinical factors that best segregate patients into risk groups. (J Thorac
Cardiovasc Surg 2013;146:768-73)Supplemental material is available online.
An accurate understanding of risk (eg, risk of recurrence) is
essential in the field of oncology. Estimates of risk guide
the development of clinical trials exploring alternative treat-
ment strategies but are also used when considering treatment
programs for individual patients. In specialties that deal with
local modalities, more precise risks are particularly helpful
(eg, risk of local recurrence). This is complicated statisticallye Department of Radiation Oncology,a the Cancer Institute Biostatistics,c and
ivision of Thoracic Surgery,e Department of Surgery, Duke Cancer Institute,
m, NC; the Department of Radiation Oncology,b Emory University, Atlanta,
e Department of Radiation Oncology,d University of North Carolina, Chapel
C; and the Department of Radiation Oncology,f Penn State Hershey Cancer
te, Hershey, Pa.
res: Authors have nothing to disclose with regard to commercial support.
d at the 55th Annual Meeting of the American Society for Therapeutic Radi-
and Oncology, October 28-31, 2013, Boston, Mass.
d for publication Feb 20, 2013; revisions received April 16, 2013; accepted
blication May 10, 2013; available ahead of print July 15, 2013.
for reprints: Chris R. Kelsey, MD, Department of Radiation Oncology, Duke
r Institute, DUMC 3085, Durham, NC 27710 (E-mail: kelse003@mc.duke.
23/$36.00
ht  2013 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.05.041
The Journal of Thoracic and Cardiovascular Surgbecause of the issue of competing risks.1 Nonetheless, pos-
sessing a reasonable appreciation of such is critical in surgical
and radiation oncology practice.
Lung cancer remains the leading cause of cancer mortal-
ity in the United States.2 Disease recurrence resulting in
death is common despite complete surgical resection,
even in patients with early-stage disease. Recurrences are
generally subdivided into those developing at local sites
(surgical margin and regional draining lymph nodes) and
those developing at distant sites. Although adjuvant chemo-
therapy can potentially decrease the risk of both local and
distant recurrence, the risk of local recurrence can also be
reduced with the use of postoperative radiation therapy.
Understanding the risk of local recurrence in resectable
non–small cell lung cancer (NSCLC) has 4 primary chal-
lenges. First, although overall recurrence rates are generally
reported in randomized lung cancer trials, patterns of failure
are often not described. This can lead to a general unaware-
ness of recurrence patterns, which has relevance to the
choice of adjuvant treatment modalities. Second, various
definitions of local recurrence have been used in the litera-
ture.3 This creates difficulty when one compares rates of lo-
cal recurrence among different studies.3,4 Third, although
multiple risk factors for local recurrence have been observed
using multivariate modeling, there are inconsistencies
between studies. Finally, estimating the aggregate risk inery c October 2013
Abbreviations and Acronyms
CI ¼ confidence interval
HR ¼ hazard ratio
LR ¼ local recurrence
LRFS ¼ local recurrence-free survival
LVI ¼ lymphovascular invasion
NSCLC ¼ non–small cell lung cancer
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San individual patient, or population, based on the presence
or absence of numerous potential factors is a challenge.
With these issues in mind, using 2 independent databases
of lung cancer patients undergoing surgery for NSCLC, we
estimated the distribution of local recurrence-free survival
(LRFS) (using a practical definition of local recurrence),
performed multivariate analyses to assess risk factors for lo-
cal recurrence, and finally performed recursive partitioning
to better understand the risk of local recurrence in defined
cohorts of lung cancer patients.METHODS
The retrospective collection of data for this study was approved by the
Institutional Review Board of each of the individual participating institu-
tions. The primary data set included all patients who underwent upfront
surgery for I-IIIA NSCLC at Duke University (Durham, NC) between
1995 and 2008. The validation data set included patients from the follow-
ing institutions: University of North Carolina (Chapel Hill, NC), Penn
State Hershey Cancer Institute (Hershey, Pa), Beth Israel Deaconess Med-
ical Center (Boston, Mass), and the Veterans Administration hospitals in
Boston, Mass, and Denver, Colo, including patients who underwent
surgery between 1996 and 2008. For both data sets, patients who received
preoperative chemotherapy and/or radiation therapy, presented with
synchronous primary tumors, or died in the immediate postoperative pe-
riod (30 days) were excluded. Patients with superior sulcus tumors or chest
wall invasion were excluded because their patterns of local recurrence are
different than patients with disease confined to the lung parenchyma and
regional lymph nodes. Because the primary objective of the study was to
evaluate the risk of local recurrence, we also excluded patients who had
positive surgical margins or who received adjuvant postoperative radiation
therapy. Because the effect of chemotherapy on local recurrence is not
clear, patients receiving adjuvant chemotherapy were included.
Disease recurrence at the surgical resection margin, ipsilateral hilum,
and/or mediastinum was defined as a local recurrence. This definition
was used because it encompasses the anatomic sites that are included
in a typical postoperative radiation field. All other sites of recurrence,
including the supraclavicular fossa and contralateral hilum, were consid-
ered distant recurrences. Patterns of recurrence were assessed by follow-
up imaging studies supplemented with invasive procedures, such as
bronchoscopy, as clinically indicated.
Statistical Analyses
The primary and validation data sets were analyzed separately and
identically. Recursive partitioning was used to fit regression trees for the
prediction of LRFS, defined as the time from surgery to local recurrence,
with distant recurrences ignored and deaths censored. The candidate pre-
dictors for both trees were sex, age, surgery type (wedge/segmentectomy
vs lobectomy/pneumonectomy), histology (squamous/adenosquamous cellThe Journal of Thoracic and Cacarcinoma, large-cell carcinoma, adenocarcinoma, and NSCLC not other-
wise specified), lymphovascular space invasion (yes/no), pleural invasion
(yes/no), number of hilar lymph nodes sampled, stage using the American
Joint Committee on Cancer, 7th edition, classification (IA, IB, IIA, IIB, or
IIIA, treated as a continuous variable), and adjuvant chemotherapy (yes/
no). Other predictors were not included in the analysis, either because
they had many missing values in the secondary data set (eg, surgical ap-
proach [open vs thoracoscopic] and grade) or because they were measures
of the same construct as pathologic stage and were highly correlated with
pathologic stage (eg, T-stage,N-stage, size of theprimary tumor, andnumber
of hilar nodes involved). We used stage as the candidate predictor instead of
one of its correlates because stage had by far the largest univariate associa-
tion with LRFS. Extent of mediastinal lymph node sampling was not
includedbecause the available data in the 2 databaseswere different (number
of stations sampled vs number of lymph nodes sampled).
Recursive partitioning is a statisticalmethod that groups patients into dis-
tinct cohorts based onmaximizing the value of log-rank tests for the clinical
end point of interest (in this case, LRFS). The first 2 cohorts are defined by
assessing all possible dichotomizations of all predictor variables, whether
categorical or continuous, to find the one dichotomization that produces
the largest log-rank test statistic. The method then repeats this assessment
within each of these 2 cohorts so that 1 of these 2 cohorts is further split
into 2 smaller subgroups. The method proceeds in this manner until a com-
plex stopping rule is met. For each cohort, 5-year LRFS rates are estimated.
Recursive partitioning was done with R’s rcart function (The R Founda-
tion for Statistical Computing, Vienna, Austria). Overgrown trees were
developed using 10 cross validations and then pruned down to a selected
number of nodes. To select the number of nodes to retain, we plotted the
mean of cross-validation errors from models of all sizes against their cor-
responding ‘‘complexity parameters.’’ We then noted the lowest-lying
point in the plot (or, in practice, the leftmost of 2 or 3 similar low-lying
points) and noted its complexity parameter value. Because each
complexity parameter value is uniquely linked to a given number of nodes,
the selected complexity parameter value determines the recommended
number of nodes. For both trees, either 2 or 3 nodes were considered
appropriate using this procedure.
The Kaplan-Meier product limit method was used to estimate 5-year
LRFS rates. The proportional hazardsmodel was used to determine the pre-
dictors of LRFS. By using the same 9 predictor variables as were used in the
recursive partitioning analyses (RPAs), the model was fit by using a back-
wards elimination procedure with a significance level to stay in the model
of 0.40.5 Predictors that were retained in the model were not assessed for
statistical significance, but their P values were used to show the strength
of evidence against the null hypothesis.RESULTS
The primary data set included 1411 patients, 199 ofwhom
developed an LR, whereas the validation data set included
889 patients, 146 of whom developed an LR. The median
follow-up among patientswithout LRwas 26months (range,
3 days to 175 months) and 33 months (range, 6 days to 175
months) in the two data sets, respectively. The primary
and validation data sets had similar LRFS distributions
(Figure E1). The data sets had 5-year LRFS rates of 77%
(95% confidence interval [CI], 0.74-0.81) and 76% (95%
CI, 0.72-0.80), respectively. Patient characteristics and
surgical/pathological details are found in Table E1. The 2
cohorts were generally similar, although there were statisti-
cally significant differences in many of the factors given the
many patients included in the analysis, despite identical
inclusion and exclusion criteria.rdiovascular Surgery c Volume 146, Number 4 769
TABLE 1. Hazard ratios from the multivariate analyses of local recurrence-free survival
Predictors*
Primary data set (n ¼ 1411) Secondary data set (n ¼ 889)
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Age (5-y increase) 0.91 0.84-0.99 .02 0.95 0.88-1.03 .29
Sex
Female
Male 1.13 0.85-1.52 .39 1.13 0.79-1.60 .51
Surgical procedure
Lobectomy/pneumonectomy
Wedge/segmentectomy 1.92 1.36-2.73 <.001 1.52 0.89-2.60 .12
No. of hilar nodes sampled (per 1 increase in node) 0.98 0.94-1.03 .43 0.98 0.95-1.01 .22
Histology
Adenocarcinoma/NSCLC NOS
Squamous/large-cell 1.75 1.31-2.34 <.001 1.43 1.02-2.00 .04
lymphovascular space invasion
No/not stated
Yes 1.32 0.95-1.83 .10 2.27 1.58-3.27 <.001
Visceral pleural invasion
No/not stated
Yes 1.78 1.30-2.43 <.001 1.24 0.77-1.98 .38
Stage (per 1 increase in unit) 1.40 1.22-1.61 <.001 1.32 1.13-1.54 <.001
Adjuvant chemotherapy
No
Yes 0.60 0.37-0.96 .03 1.66 1.05-2.61 .03
CI, Confidence interval; NSCLC, non–small cell lung cancer; NOS, not otherwise specified. *For dichotomous predictors, the first value listed is the reference value (ie, the
numerator of the hazard ratio).
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In the proportional hazards model, the size of the associ-
ation between predictors of local recurrence depended on
the data set (Table 1). In the primary data set, the factors
most strongly associated with shorter LRFS included sublo-
bar resection, compared with lobectomy/pneumonectomy
(hazard ratio [HR], 1.92; 95% CI, 1.36-2.73); squamous
or large-cell histology, compared with adenocarcinoma/
NSCLC not otherwise specified (HR, 1.75; 95% CI, 1.31-
2.34); visceral pleural invasion, compared with no pleural
invasion (HR, 1.78; 95% CI, 1.30-2.43); and higher stage
(HR for a 1-unit increase in stage, 1.40; 95% CI, 1.22-
1.61). All 4 of these associations had P values< .001.
In the validation data set, the factors most strongly asso-
ciated with a shorter LRFS included lymphovascular space
invasion (LVI) compared with no invasion (HR, 2.29; 95%
CI, 1.60-3.29) and higher stage (HR for a 1-unit increase in
stage, 1.29; 95% CI, 1.11-1.50) (Table 1). Both of these
associations had P values< .001.
Recursive Partitioning Analysis
The primary RPA identified 3 terminal nodes based on
stage and histology: stage I/adenocarcinoma or NSCLC
not otherwise specified, stage I/squamous or large cell,
and stage II-IIIA (Figure 1, A). The 5-year LRFS rates
(and 95% CIs) for each node were 87% (95% CI, 0.83-
0.90), 72% (95% CI, 0.65-0.79), and 62% (95% CI,
0.55-0.69), respectively (Figure 1, B).770 The Journal of Thoracic and Cardiovascular SurgThe validation RPA identified 3 terminal nodes based on
LVI and stage: no LVI/stage IA, no LVI/stage IB-IIIA, and
LVI (Figure 2, A). The 5-year LRFS rates (and 95%CIs) for
each node were 82% (95% CI, 0.76-0.88), 73% (95% CI,
0.69-0.80), and 58% (95% CI, 0.47-0.69), respectively
(Figure 2, B).
DISCUSSION
By using a definition of local recurrence that includes
those anatomic sites that are included in a typical postoper-
ative radiation field, the risk of local recurrence was the
same in the primary and validation data sets. The 5-year
LRFS rates were 77% and 76%, emphasizing that local re-
currence remains an obstacle for cure, even in resected
NSCLC. Given the negative impact of conventional postop-
erative radiation therapy in an unselected population of pa-
tients with early-stage NSCLC,6 there is a need to identify
and validate a population of patients at highest risk who
would be optimal for further study of postoperative radia-
tion therapy.
By using standard clinical and pathological factors, we
examined whether recursive partitioning would stratify pa-
tients into risk groups with widely varying rates of local re-
currence. Although recursive partitioning did segregate
patients into distinct groups, the size of the risk differences
between the RPA nodes was smaller than we had hoped, on
the order of approximately a 10% to 20% absolute differ-
ence in risk. Such differences might be too small toery c October 2013
FIGURE 1. A, Results of the recursive partitioning analysis (RPA) of the
primary data set. B, Five-year local recurrence-free survival rates are
shown according to RPA node. NSCLC, Non–small cell lung cancer;
NOS, not otherwise specified.
FIGURE 2. A, Results of the recursive partitioning analysis (RPA) of the
validation data set. B, Five-year local recurrence-free survival rates are
shown according to RPA node. LVI, Lymphovascular invasion.
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operative radiation therapy. Another disappointment was
that the resulting trees differed between the 2 data sets.
This may be due, in part, to the large correlation among
the risk factors, because multicollinearity is known to pro-
duce unstable results.
Although a defined population of patients with resected
NSCLC was identified prospectively to be included in the
study, there were some differences between the 2 groups
of patients (Table E1), perhaps reflecting geographic varia-
tions in disease presentation, tumor characteristics, and
treatment approaches. Furthermore, despite a consistent
definition of local recurrence, the multivariate models of
local recurrence differed between the data sets. This was
also reflected in the disparate results obtained with recursive
partitioning, although both data sets implicated pathologic
stage as being a major predictive factor.
Prior studies have identified several potential risk factors for
local recurrence. Many relate to the extent and quality of sur-
gery. These include more limited surgical procedures (wedge
or segmentectomy),4,7-13 positive surgical margins,10,14-16
and lack of or limited mediastinal sampling.11,17,18 Other
factors relate to the pathologic findings, includingThe Journal of Thoracic and Castage,10,12,16 extent of regional lymph node involve-
ment,14,19 size of the primary tumor,10,13,20 squamous histol-
ogy,12,21 visceral pleural invasion,13,19 and lymphovascular
space invasion.4,12,20 Patient-related factors, such as smok-
ing history18 and comorbid disease,22 may also be contribu-
tory. Randomized studies have shown that adjuvant
radiation therapy decreases the risk of local recurrence but
may negatively affect long-term survival, at least for an
unselected population with early-stage disease.16,23-26
The effect of chemotherapy on local recurrence is not
clear.22,27,28
Although multiple surgical and pathologic factors, previ-
ously outlined, have been associated with a higher risk of
local recurrence after surgery for NSCLC, these factors
have not been consistent across studies (Table 2). Further-
more, most studies have not performed comprehensive mul-
tivariate modeling to identify factors independently
associated with local recurrence. Thus, consistently defin-
ing cohorts at highest risk of local recurrence in NSCLC
has proven elusive.
There are limitations with our analysis. Patients were
treated over many years at multiple institutions and un-
doubtedly there has been an evolution in surgicalrdiovascular Surgery c Volume 146, Number 4 771
TABLE 2. Studies using multivariate modeling to assess risk factors for local recurrence
Risk factor
Kelsey12
(n ¼ 975)
Hung18
(n ¼ 756)
Varlotto22
(n ¼ 373)
Saynak20
(n ¼ 335)
Lee10
(n ¼ 211)
Lopez Guerra13
(n ¼ 1402)
Patient characteristics
Age     
Sex     
Diabetes  þ
Smoking history þ 
PET-CT staging 
Surgical characteristics
Open/VATS  
Sublobar resection þ  þ þ
Positive margins   þ
Lymph node sampling  þ 
Pathologic characteristics
Right vs left  
Stage þ    
Extent of regional lymph node involvement  
Tumor size   þ  þ
Histologic grade    
Squamous histology þ    
Visceral pleural invasion     þ
Lymphovascular space invasion  þ þ 
Adjuvant therapy
Radiation therapy 
Chemotherapy  þ 
Some studies evaluated numerous additional factors (all positive factors listed in the table). þ, Associated with local recurrence; , not associated with local recurrence; blank
cells, the factor was not assessed; PET, positron emission tomography; CT, computed tomography; VATS, video-assisted thoracoscopic surgery.
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differences among the institutions regarding surgical exper-
tise and technique, pathological assessment and interpreta-
tion, including histologic classification,29 lymph node
identification and ascertainment of involvement,30 and/or
reporting of lymphovascular space invasion and visceral
pleural invasion. Serial imaging to assess for local recur-
rence was not standardized between or within centers.
Thus, some local recurrences were probably not identified.
Furthermore, local recurrences were largely identified using
imaging studies that have limitations with both sensitivity
and specificity. Finally, only those factors that were avail-
able from each institution’s database were studied. It is
possible other clinical or pathological factors, such as
comorbidities or smoking status, could be important. None-
theless, this endeavor is one of the largest studies evaluating
local recurrence in operable NSCLC and included data from
multiple institutions.
This study, in concert with previous analyses evaluating
risk factors for local recurrence, demonstrates that, al-
though standard clinical and pathologic factors can be use-
ful, they are unlikely to provide optimal discrimination
between low- and high-risk cohorts. More refined methods
to assess risk are necessary before an enriched population of
patients can be identified for further study of postoperative
radiation therapy. Whether biomarkers or genomic772 The Journal of Thoracic and Cardiovascular Surgsignatures will help in this regard is, at present, unknown,
but should be explored. Furthermore, more customized
and conformal radiation fields than have been historically
used may be advantageous for patients with early-stage dis-
ease, as was shown in a randomized trial that showed a ben-
efit for postoperative radiation therapy in stage I NSCLC.26
We advocate good surgical and pathologic practices that
may decrease the risk of local recurrence, including rigorous
preoperative staging, complete resection with negative mar-
gins, adequate lymph node sampling/dissection and exami-
nation, and multidisciplinary assessment when appropriate.
CONCLUSIONS
By using 2 large independent data sets, we observed dis-
cordance regarding the parameters that best segregate pa-
tients into risk groups of local recurrence, although stage
appears to be an important factor. Furthermore, although re-
cursive partitioning is able to define subgroups at variable
risk of local recurrence, the differences in the risk groups
are modest. More precise methods of assessing risk are nec-
essary to optimally define high-risk patients.
References
1. Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved method-
ology for analyzing local and distant recurrence. J Clin Oncol. 1990;8:548-55.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin.
2010;60:277-300.ery c October 2013
Kelsey et al General Thoracic Surgery
G
T
S3. Kelsey CR,MarksLB,Wilson LD. Postoperative radiation therapy for lung cancer:
where do we stand? Oncology (Williston Park). 2008;22:301-10; discussion 10,
14-5, 19.
4. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM,
DeCampMM. Varying recurrence rates and risk factors associated with different
definitions of local recurrence in patients with surgically resected, stage I non-
small cell lung cancer. Cancer. 2010;116:2390-400.
5. Harrell FE. Regression Modeling Strategies With Applications to Linear Models,
Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001.
6. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-
cell lung cancer: systematic review and meta-analysis of individual patient
data from nine randomised controlled trials. Lancet. 1998;352:257-63.
7. Ginsberg RJ, Rubinstein LV, Lung Cancer Study Group. Randomized trial of
lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann
Thorac Surg. 1995;60:615-22; discussion 22-3.
8. Harpole DH Jr, Herndon JE II, YoungWG Jr, WolfeWG, Sabiston DC Jr. Stage I
nonsmall cell lung cancer: a multivariate analysis of treatment methods and
patterns of recurrence. Cancer. 1995;76:787-96.
9. Warren WH, Faber LP. Segmentectomy versus lobectomy in patients with stage
I pulmonary carcinoma: five-year survival and patterns of intrathoracic recur-
rence. J Thorac Cardiovasc Surg. 1994;107:1087-93; discussion 93-4.
10. Lee JH, Machtay M, Kaiser LR, Friedberg JS, Hahn SM, McKenna MG, et al.
Non-small cell lung cancer: prognostic factors in patients treated with surgery
and postoperative radiation therapy. Radiology. 1999;213:845-52.
11. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al.
Incidence of local recurrence and second primary tumors in resected stage I lung
cancer. J Thorac Cardiovasc Surg. 1995;109:120-9.
12. Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D’Amico TA, et al. Local
recurrence after surgery for early stage lung cancer: an 11-year experience with
975 patients. Cancer. 2009;115:5218-27.
13. Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, et al. Risk
factors for local and regional recurrence in patients with resected N0-N1 non-
small-cell lung cancer, with implications for patient selection for adjuvant radi-
ation therapy. Ann Oncol. 2013;24:67-74.
14. Hsu HC, Wang CJ, Huang EY, Sun LM. Post-operative adjuvant thoracic radio-
therapy for patients with completely resected non-small cell lung cancer with
nodal involvement: outcome and prognostic factors. Br J Radiol. 2004;77:43-8.
15. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Trastek VF, et al.
Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer
according to regression tree analyses of recurrence risks. Ann Thorac Surg. 1997;
64:1402-7; discussion 1407-8.
16. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Trastek VF, et al.
The impact of surgical adjuvant thoracic radiation therapy for patients with non-
small cell lung carcinoma with ipsilateral mediastinal lymph node involvement.
Cancer. 1997;80:1399-408.
17. Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity,
survival, and site of recurrence after mediastinal lymph-node dissection versusThe Journal of Thoracic and Casystematic sampling after complete resection for non-small cell lung cancer.
Ann Thorac Surg. 2005;80:268-74; discussion 274-5.
18. Hung JJ, Jeng WJ, Hsu WH, Chou TY, Huang BS, Wu YC. Predictors of death,
local recurrence, and distant metastasis in completely resected pathological
stage-I non-small-cell lung cancer. J Thorac Oncol. 2012;7:1115-23.
19. Fujimoto T, Cassivi SD, Yang P, Barnes SA, Nichols FC, Deschamps C,
et al. Completely resected N1 non-small cell lung cancer: factors affecting
recurrence and long-term survival. J Thorac Cardiovasc Surg. 2006;132:
499-506.
20. Saynak M, Veeramachaneni NK, Hubbs JL, Nam J, Qaqish BF, Bailey JE, et al.
Local failure after complete resection of N0-1 non-small cell lung cancer. Lung
Cancer (Amsterdam, Netherlands). 2011;71:156-65.
21. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Lange CM, et al.
Factors predicting patterns of recurrence after resection of N1 non-small cell
lung carcinoma. Ann Thorac Surg. 1999;68:1171-6.
22. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM,
Decamp MM. Factors associated with local and distant recurrence and sur-
vival in patients with resected nonsmall cell lung cancer. Cancer. 2009;115:
1059-69.
23. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on
completely resected stage II and stage III epidermoid cancer of the lung.N Engl J
Med. 1986;315:1377-81.
24. Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, et al. A study of
postoperative radiotherapy in patients with non-small-cell lung cancer: a random-
ized trial. Int J Radiat Oncol Biol Phys. 2000;47:925-9.
25. Mayer R, Smolle-Juettner FM, Szolar D, Stuecklschweiger GF, Quehenberger F,
Friehs G, et al. Postoperative radiotherapy in radically resected non-small cell
lung cancer. Chest. 1997;112:954-9.
26. Trodella L, Granone P, Valente S, Valentini V, Balducci M, Mantini G, et al.
Adjuvant radiotherapy in non-small cell lung cancer with pathological stage
I: definitive results of a phase III randomized trial. Radiother Oncol. 2002;
62:11-9.
27. Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D,
et al. Long-term results of the international adjuvant lung cancer trial evaluating
adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol.
2010;28:35-42.
28. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-
Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in
patients with completely resected stage IB-IIIA non-small-cell lung cancer
(Adjuvant Navelbine International Trialist Association [ANITA]): a randomised
controlled trial. Lancet Oncol. 2006;7:719-27.
29. Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R.
Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive
cases. Hum Pathol. 1985;16:569-79.
30. Ramirez RA, Wang CG, Miller LE, Adair CA, Berry A, Yu X, et al. Incomplete
intrapulmonary lymph node retrieval after routine pathologic examination of
resected lung cancer. J Clin Oncol. 2012;30:2823-8.rdiovascular Surgery c Volume 146, Number 4 773
FIGUREE1. Kaplan-Meier curves of local recurrence-free survival in the
primary data set (A) and validation data set (B).
TABLE E1. Patient and treatment characteristics
Characteristic
Primary
data set
(n ¼ 1411)
Validation
data set
(n ¼ 889)
P
value
Factors used in multivariate and recursive partitioning analyses
Age, y
Median 68 67 .09
Range 21-93 35-96
Unknown 2
Sex
Male 747 53 534 60 <.001
Female 664 47 353 40
Unknown 2 0.2
Surgical procedure
Wedge/segmentectomy 285 20 103 12 <.001
Lobectomy* 1048 74 706 79
Pneumonectomy 78 6 80 9
Hilar lymph node sampling
Yes 1150 82 770 87 .001
No 261 18 119 13
Histology
Adenocarcinoma 682 48 429 48 <.001
Squamous celly 540 39 377 42
Large cell 87 6 43 5
NSCLC NOS 102 7 40 4
Lymphovascular invasion
Yes 297 21 155 17 .03
No/not stated 1113 79 734 83
Visceral pleural invasion
Yes 314 22 95 11 <.001
No/not stated 1097 78 794 89
Pathologic stage
IA 609 43 426 48 .006
IB 382 27 203 23
IIA 231 16 153 17
IIB 108 8 78 9
IIIA 81 6 29 3
Adjuvant chemotherapy
Yes 141 10 106 12 .14
No 1270 90 783 88
Factors not used in multivariate and recursive partitioning analyses
Mediastinal lymph node sampling
Yes 1234 87 694 78 <.001
No 177 13 195 22
Histologic differentiation
Well 130 9 136 15 <.001
Moderate 641 45 419 47
Poor 463 33 286 32
Unknown 177 13 48 6
Size, cmz .91
Median 2.6 2.7
Range 0.5-14 0.3-15
Values are given as number (%) unless otherwise indicated. NSCLC, Non–small cell
lung cancer; NOS, not otherwise specified. *Including bilobectomy and sleeve lobec-
tomy. yIncluding adenosquamous (n ¼ 15 in primary and n ¼ 20 in validation
cohorts). zThere were 4 and 9 missing values on size in the primary and validation
cohorts, respectively.
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